U.S. Biomarkers Advanced Technologies Market Size, Share & Forecast 2026–2032
Report Highlights
- ✓Country: United States
- ✓Market: Biomarkers Advanced Technologies
- ✓Market Size 2024: USD 21.8 billion
- ✓Market Size 2032: USD 47.4 billion
- ✓CAGR: 10.2%
- ✓Base Year: 2025
- ✓Forecast Period: 2026–2032
Analyst Recommendation — Prioritize Prospective Utility Evidence: Diagnostics developers and institutional investors should commit capital before the end of 2026 to generating prospective clinical utility data for Medicare coverage under CMS's Transitional Coverage for Emerging Technologies pathway, because coverage determinations will set reimbursement for the next decade.
U.S. Biomarker Technologies: Market Overview
The U.S. biomarker technologies market was valued at USD 21.8 billion in 2024 and is forecast to reach USD 47.4 billion by 2032, according to our estimates, making the country the largest single national market for biomarker platforms globally. Revenue is spread across sequencing and proteomics instruments, reagents, assay services, and clinical testing. Private companies have led commercialization, with Illumina, Thermo Fisher Scientific, and Guardant Health setting the pace, while government has shaped the market mainly by funding discovery and setting coverage rules.
Policy has shaped the market's current form in two distinct ways. The National Institutes of Health, through the All of Us Research Program funded under the 21st Century Cures Act, built large biobank datasets that industry partners now use to validate assays. Meanwhile, the Centers for Medicare and Medicaid Services sets reimbursement rules that determine which tests reach patients, a role where the public sector clearly dominates commercial strategy.
Policy-Driven Growth in U.S. Biomarker Technologies
The 21st Century Cures Act of 2016 is the primary legislative driver. It authorized a USD 4.8 billion NIH Innovation Account across fiscal years 2017 to 2026, funding the All of Us Research Program, and added Section 515B to the Federal Food, Drug, and Cosmetic Act, creating the FDA Breakthrough Devices Program. Breakthrough designation accelerates review for biomarker-based diagnostics, pulling commercial launches forward and expanding the installed base of sequencing and immunoassay platforms in hospital laboratories.
Coverage policy is the second mechanism. Medicare's Molecular Diagnostic Services (MolDX) program, run by Palmetto GBA, requires analytical and clinical validity evidence before coverage. Section 216 of the Protecting Access to Medicare Act of 2014 created the Advanced Diagnostic Laboratory Test designation, which pays qualifying tests higher rates and rewards firms that publish validation studies. Executive Order 14081 of September 2022 adds a third mechanism by directing federal agencies to expand biomanufacturing capacity.
Regulatory Barriers and Compliance Costs
Laboratory-developed tests are governed by the Clinical Laboratory Improvement Amendments of 1988, administered by CMS with CDC technical support. CLIA certification requires laboratories to meet personnel, proficiency testing, and quality control standards before testing patients. Smaller developers commonly report that initial certificate issuance through state survey agencies takes several months, delaying revenue from new biomarker assays.
Premarket requirements add a second layer. Companion diagnostics classified as Class III devices require a Premarket Approval application under 21 CFR Part 814, with a 180-day statutory review goal that is routinely exceeded in practice. Biomarker developers also face state genetic privacy statutes and HHS Office for Civil Rights enforcement under HIPAA, adding data-governance costs that CMS payment rules do not reimburse.
Policy-Created Opportunities in the United States
The Transitional Coverage for Emerging Technologies pathway, finalized by CMS in August 2024, creates a fast route to coverage. Under TCET, CMS selects a limited number of breakthrough devices each year for coverage with evidence development, which gives biomarker developers with Breakthrough Devices designation a defined path to national reimbursement. Developers that align trial design with TCET criteria can convert regulatory advantage into payment within a single product cycle.
Federal research procurement offers a second opportunity. The Department of Defense Congressionally Directed Medical Research Programs funds biomarker validation studies across cancer and neurological disease, while the Department of Veterans Affairs Million Veteran Program, which passed one million enrolled participants in 2023, supplies genomic and phenotypic datasets to qualified developers. Firms that build assays on these cohorts reduce their validation costs substantially.
Market at a Glance
| Metric | Value |
|---|---|
| Market Size 2024 | USD 21.8 billion |
| Market Size 2032 | USD 47.4 billion |
| Growth Rate (CAGR) | 10.2% |
| Most Critical Decision Factor | Medicare coverage evidence under MolDX and TCET |
| Largest Region | California and Massachusetts biomarker clusters |
| Competitive Structure | Consolidated at the top, fragmented in the mid-tier |
Leading Market Participants
- Illumina
- Thermo Fisher Scientific
- Roche Diagnostics
- Abbott Laboratories
- Danaher
- Agilent Technologies
- Bio-Rad Laboratories
- Guardant Health
- Exact Sciences
- Natera
Regulatory and Policy Environment
The primary legislation is the Federal Food, Drug, and Cosmetic Act, as amended by the 21st Century Cures Act, alongside the Clinical Laboratory Improvement Amendments of 1988 and Section 216 of the Protecting Access to Medicare Act of 2014. The FDA's Center for Devices and Radiological Health regulates companion diagnostics under 21 CFR Parts 809 and 814, CMS administers CLIA and the Clinical Laboratory Fee Schedule, and the HHS Office for Civil Rights enforces HIPAA. FDA's 2024 LDT final rule was vacated by the Eastern District of Texas in March 2025, leaving laboratories under CLIA alone.
Compared with regional peers, the U.S. framework is more permissive for in-house tests. The EU In Vitro Diagnostic Regulation, Regulation (EU) 2017/746, applies full conformity assessment to laboratory-made tests with phased transition deadlines running to 2027 and 2029. MDUFA V and PDUFA VII both expire on September 30, 2027, so the reauthorization negotiations in 2026 will determine how FDA treats biomarker qualification and review timelines.
Long-Term Policy Outlook for U.S. Biomarker Technologies
By 2032, reauthorization of MDUFA and PDUFA will likely be the largest policy event for the market, with biomarker qualification and companion diagnostic review timelines at the center of negotiations. CMS is expected to move more coverage decisions from local MolDX determinations to national coverage determinations, which would standardize evidence requirements across the country. Developers with multi-year clinical utility datasets will gain the most from this consolidation.
Data governance will also reshape the market. State laws such as the Washington My Health My Data Act, effective in March 2024, extend consumer health data protection beyond HIPAA, raising consent and storage costs for biomarker developers. Congressional proposals targeting biotechnology suppliers of concern will push laboratories toward domestic instrument and reagent sourcing by the early 2030s.
Frequently Asked Questions
Market Segmentation
- Next-Generation Sequencing
- Mass Spectrometry Proteomics
- Multiplex Immunoassays
- Liquid Biopsy Platforms
- Others
- Hospitals and Health Systems
- Reference Laboratories
- Pharmaceutical and Biotechnology Companies
- Academic and Government Research
- Others
- Oncology Companion Diagnostics
- Cardiovascular Risk Stratification
- Neurodegenerative Disease Screening
- Infectious Disease Surveillance
- Pharmacodynamic Monitoring
Table of Contents
Research Framework and Methodological Approach
Information
Procurement
Information
Analysis
Market Formulation
& Validation
Overview of Our Research Process
MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.
1. Data Acquisition Strategy
Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.
- Company annual reports & SEC filings
- Industry association publications
- Technical journals & white papers
- Government databases (World Bank, OECD)
- Paid commercial databases
- KOL Interviews (CEOs, Marketing Heads)
- Surveys with industry participants
- Distributor & supplier discussions
- End-user feedback loops
- Questionnaires for gap analysis
Analytical Modeling and Insight Development
After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.
2. Market Estimation Techniques
MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.
Bottom-up Approach
Aggregating granular demand data from country level to derive global figures.
Top-down Approach
Breaking down the parent industry market to identify the target serviceable market.
Supply Chain Anchored Forecasting
MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.
Supply-Side Evaluation
Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.
3. Market Engineering & Validation
Market engineering involves the triangulation of data from multiple sources to minimize errors.
Extensive gathering of raw data.
Statistical regression & trend analysis.
Cross-verification with experts.
Publication of market study.
Client-Centric Research Delivery
MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.